Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentle nasal breeze unclog the Lungs' smallest airways?

NCT ID NCT07750613

Knowledge-focused Sponsor: ADIR Association Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study looks at how nasal high-flow therapy—a device that delivers warm, moist air through small nasal tubes—affects the airways of people with severe chronic obstructive pulmonary disease (COPD). Researchers will measure airway resistance and other lung mechanics using a non-invasive test called oscillometry, which requires only quiet breathing. Twenty adults with stable severe COPD who have never used this therapy will receive it for four hours, with measurements taken at several time points. The goal is to see if the therapy produces measurable, time-dependent changes in the small airways, which could help explain how it might ease breathing.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Heated humidified nasal high-flow therapy delivered through nasal cannulas
What this could lead to
If this works, it could help doctors understand how nasal high-flow therapy affects the small airways in COPD, potentially guiding better use of this treatment to ease breathing.
What could go wrong
This is a small, early physiological study with only 20 participants, so results may not apply to everyone with COPD. The therapy is generally well-tolerated, but some people may find the nasal cannula uncomfortable or experience minor irritation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>18 years and \<85 years; * Chronic obstructive pulmonary disease classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) spirometric grade III or IV; * Modified Medical Research Council dyspnea score ≥2; * Completed a pulmonary rehabilitation program at the study center; * Clinically stable, defined as no exacerbation and no treatment change during the previous 4 weeks; * With or without long-term oxygen therapy; * Never previously used nasal high-flow therapy; * Affiliated with a French social security system; * Able to read and understand the participant information and provide written informed consent. Non-inclusion Criteria: * Under legal guardianship or curatorship; * Confirmed or suspected pregnancy; * Unable to provide informed consent; * Primary diagnosis of another chronic obstructive respiratory disease, such as asthma or primary bronchiectasis; * Severe or unstable cardiovascular disease, including uncontrolled cardiac arrhythmia, severe heart failure, recent myocardial infarction, or unstable angina; * Hemodynamic instability. Exclusion Criteria: • None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease (COPD)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ADIR Association

    Rouen, Normandy, 76000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.